Bad Pharma and Academics what bad news are you hiding

Golder S, Loke YK, Wright K, Norman G. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review. PLoS Med. 2016;13:e1002127.

BACKGROUND:We performed a systematic review to assess whether we can quantify the underreporting of adverse events (AEs) in the published medical literature documenting the results of clinical trials as compared with other nonpublished sources, and whether we can measure the impact this underreporting has on systematic reviews of adverse events.
METHODS AND FINDINGS:Studies were identified from 15 databases (including MEDLINE and Embase) and by handsearching, reference checking, internet searches, and contacting experts. The last database searches were conducted in July 2016. There were 28 methodological evaluations that met the inclusion criteria. Of these, 9 studies compared the proportion of trials reporting adverse events by publication status. The median percentage of published documents with adverse events information was 46% compared to 95% in the corresponding unpublished documents. There was a similar pattern with unmatched studies, for which 43% of published studies contained adverse events information compared to 83% of unpublished studies. A total of 11 studies compared the numbers of adverse events in matched published and unpublished documents. The percentage of adverse events that would have been missed had each analysis relied only on the published versions varied between 43% and 100%, with a median of 64%. Within these 11 studies, 24 comparisons of named adverse events such as death, suicide, or respiratory adverse events were undertaken. In 18 of the 24 comparisons, the number of named adverse events was higher in unpublished than published documents. Additionally, 2 other studies demonstrated that there are substantially more types of adverse events reported in matched unpublished than published documents. There were 20 meta-analyses that reported the odds ratios (ORs) and/or risk ratios (RRs) for adverse events with and without unpublished data. Inclusion of unpublished data increased the precision of the pooled estimates (narrower 95% confidence intervals) in 15 of the 20 pooled analyses, but did not markedly change the direction or statistical significance of the risk in most cases. The main limitations of this review are that the included case examples represent only a small number amongst thousands of meta-analyses of harms and that the included studies may suffer from publication bias, whereby substantial differences between published and unpublished data are more likely to be published.
CONCLUSIONS: There is strong evidence that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study. The inclusion of unpublished data can also reduce the imprecision of pooled effect estimates during meta-analysis of adverse events.

Approximately half of studies published on new medical treatments leave out at least some of the adverse effects they uncovered, according to a recent analysis in PLOS Medicine. A team of British researchers conducted the review after coming across individual cases of missing side effects in medical literature, which includes studies from pharmaceutical companies, hospitals and academics. To determine how widespread the problem was, they analyzed 28 journal articles that together cross-checked the published data from more than 500 clinical studies with their original data sets. The review’s results quantitatively confirm that some drugs may have side effects not even doctors know about—which means treatments may not be as safe as they appear.

The solution is not to scrabble around as the authours of this paper have had to do but is important that the primary data is available especially for licenced drugs. So you need to see the regulatory submission of the drug study.

A few companies (Novartis, Roche Sanofi etc) have signed up to this and there is a website where you can request the data, but problem is they have only agreed to do this from 2014 onwards.

Alemtuzumab was submitted to regulators in 2012 and so they don’t have to make data available.  But you can request it.

It is now two months since, I made such a request…It makes you think what is being hidden?

About the author



  • It has to be raw data to answer specific questions about efficacy and safety, as I have all their editied data already 🙂 so know they must have the data to address the specific questions I have.

  • Do not give up. Keep asking, officially but also unofficially every time you are publicly talking about the drug, or discussing with one of their employee. It might take months/years, but very likely you will get the data set. And it is extremely important for all of us, safety is a key decision driver in choosing a DMT.

  • We need to push our neurologists to report. This has been a fight I've been losing but still trying. I have unusual side affects on Tecfidera (menstrual cycle changes and lowered platelet count) and have had a tough time getting my neurologist to listen. I keep pushing not because I want off the drug but because I think its important that every side affect be tracked. Maybe they are afraid we wouldn't take the drugs if we actually knew all the possible side affects?

By MouseDoctor



Recent Posts

Recent Comments